Nykode Therapeutics AS (OSL:NYKD)

Nykode Therapeutics AS Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	44.79	60.29	115.4	162.6	206.39	216.23
Trading Asset Securities	-	-	-	-	-	12.17
Cash & Short-Term Investments	44.79	60.29	115.4	162.6	206.39	228.4
Cash Growth	-36.00%	-47.76%	-29.03%	-21.21%	-9.64%	9.39%
Accounts Receivable	-	-	-	-	2.54	23.75
Other Receivables	3.4	0.91	0.91	1.07	1.79	2.41
Receivables	3.4	0.91	0.91	1.07	4.33	26.16
Prepaid Expenses	-	0.7	0.76	2.01	1.15	1.3
Total Current Assets	48.19	61.89	117.07	165.68	211.87	255.86
Property, Plant & Equipment	4.41	5.68	7.74	10.52	9.53	9.17
Other Intangible Assets	0.07	0.07	0.07	0.07	0.03	0.03
Long-Term Deferred Tax Assets	0.05	0.08	-	-	-	-
Long-Term Deferred Charges	-	-	-	-	-	0.48
Other Long-Term Assets	33.39	32.22	28.6	31.92	0.05	0.02
Total Assets	86.11	99.96	153.48	208.19	221.48	265.56

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	2.69	1.11	0.86	1.33	2.31	2.75
Accrued Expenses	-	3.37	3.62	6.08	7.58	9.3
Current Portion of Leases	1.18	1.25	1.29	1.46	1.15	1.35
Current Income Taxes Payable	-	-	0.02	-	0.08	0.03
Current Unearned Revenue	-	-	-	8.34	19.87	16.26
Other Current Liabilities	0.32	0.46	3.3	3.41	8	1.69
Total Current Liabilities	4.18	6.19	9.1	20.61	38.99	31.37
Long-Term Leases	0.61	1.3	2.15	4.27	4.37	5.82
Long-Term Deferred Tax Liabilities	-	-	5.2	12.05	21.08	29.4
Other Long-Term Liabilities	0.94	0.93	0.82	0	0.03	4.91
Total Liabilities	5.73	8.42	17.27	36.93	64.46	71.5

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.37	0.37	0.37	0.37	0.34	0.33
Additional Paid-In Capital	96.71	96.71	128.99	128.99	83.32	81.53
Retained Earnings	-32.48	-21.18	-8.76	29.56	64.71	107.46
Comprehensive Income & Other	15.79	15.65	15.62	12.35	8.65	4.74
Shareholders' Equity	80.39	91.54	136.21	171.26	157.02	194.06
Total Liabilities & Equity	86.11	99.96	153.48	208.19	221.48	265.56

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1.79	2.55	3.44	5.73	5.51	7.17
Net Cash (Debt)	43.01	57.74	111.96	156.88	200.87	221.23
Net Cash Growth	-35.70%	-48.43%	-28.63%	-21.90%	-9.20%	6.10%
Net Cash Per Share	0.12	0.18	0.34	0.52	0.69	0.77
Filing Date Shares Outstanding	359.25	326.55	326.55	326.55	294.69	289.62
Total Common Shares Outstanding	359.25	326.55	326.55	326.55	294.69	289.62
Working Capital	44.01	55.7	107.97	145.07	172.89	224.49
Book Value Per Share	0.22	0.28	0.42	0.52	0.53	0.67
Tangible Book Value	80.31	91.47	136.14	171.19	156.99	194.02
Tangible Book Value Per Share	0.22	0.28	0.42	0.52	0.53	0.67
Machinery	-	5.03	5.02	4.97	3.44	1.46

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 27, 2026

Data Sources Report a data error